Trial reportPhytotherapy research : PTR2026
A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Ashwagandha Root Extract Capsule on Skin and Hair Health in Healthy Adults.
Trial report in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hair loss and skin conditions have a detrimental influence on personality, health, and quality of life (QoL). Herbs from Ayurveda, such as ashwagandha having multimodal biological activities, are being researched as potential remedies for this issue. This prospective, randomized, double-blind, placebo-controlled comparative trial was carried out to evaluate the safety and efficacy of standardized Ashwagandha root extract on skin and hair related metrics in healthy adults. Participants between 18 and 60 years with hair loss or skin conditions were randomized to receive either an Ashwagandha capsule (300 mg/twice daily) or a Placebo treatment. The participants were assessed on Day 1 and 75 for change in efficacy indices, which included Transepidermal water loss (TEWL), TrichoScan hair parameters, and quality of life (QoL). The Ashwagandha group demonstrated greater improvement in TEWL and a substantial improvement in hair-related parameters (density, growth, anagen, telogen, and anagen: telogen ratio) compared to Placebo (p < 0.05) on day 75. When compared to the placebo, the Ashwagandha group demonstrated significant improvement in skin specific QoL, evidenced by a lower DLQI score (p < 0.05). Similarly, hair-specific QoL was considerably improved, as revealed by a lower score on the Hair-specific Skindex-29 compared to the Placebo (p < 0.05). The oral administration of Ashwagandha root extract for 75 days improved skin-related and hair-related parameters. No adverse drug events were encountered. Therefore, Ashwagandha root extract can hold promises for enhancing the skin and hair quality in healthy adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.